Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer

Seminars in Oncology

Volumn 23, Issue 1 SUPPL. 1, 1996, Pages 33-36

  Luck, H J ^a   Thomssen, C ^a   DuBois, A ^a   Lisboa, B W ^a   Untch, M ^a   Kuhnle, H ^a   Konecny, G ^a   Janicke, F ^a   Meerpohl, H G ^a   Lindner, C ^a   Hecker, D ^a   Diergarten, K ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ALOPECIA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION;

EID: 0029871456     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)